CD80-Mediated T-Cell Suppression by Cancer Stem-like Cells in Head and Neck Squamous Cell Carcinoma

TL;DR

This study shows that CD80 in cancer stem-like cells suppresses T-cell immunity in head and neck cancer, and blocking CD80 could improve treatment responses.

Contribution

The novel finding is that CD80 in cancer stem-like cells suppresses T-cell immunity and that CD80 inhibition enhances antitumor effects in HNSCC.

Findings

CD80 is highly expressed in cancer stem-like cells and correlates with poor response to neoadjuvant chemoimmunotherapy.

CD80 inhibition activates Th1 immune responses and increases T cell cytotoxicity in preclinical HNSCC models.

Blocking CD80 reduces tumor burden and enhances antitumor immunity in head and neck squamous cell carcinoma.

Abstract

Neoadjuvant chemoimmunotherapy has emerged as a promising treatment strategy for head and neck squamous cell carcinoma (HNSCC). There is an urgent need to improve patient responses to this approach. In this study, we aim to elucidate the mechanisms underlying poor response to neoadjuvant chemoimmunotherapy and to identify strategies to enhance therapeutic efficacy in HNSCC. We identified a cancer stem-like cell (CSC) population enriched in patients with partial response (PR) to neoadjuvant chemoimmunotherapy, characterized by high CD80 expression. CD80 was likewise highly expressed in ALDHhighCD44+ and BMI1+ populations. Functionally, CD80 knockdown attenuated tumor-sphere-forming capacity and reduced the migration and invasion of tumor cells, whereas CD80 overexpression potentiated these pro-tumorigenic activities. Moreover, CD80 inhibition activated signaling pathways of Th1 immune responses and IL-2 production. CD80 blockade enhanced T cell cytotoxicity. In preclinical HNSCC models, inhibition of CD80 significantly decreased tumor burden, accumulated CD8+ T cells, and increased the production of cytotoxic effector molecules. Our data demonstrated that CD80 modulated tumor-cell stemness and malignant phenotype while restraining antitumor T cell immunity. Targeting CD80 augments antitumor immunity and provides a compelling strategy to enhance treatment responses to neoadjuvant chemoimmunotherapy in HNSCC.

Figures